Lexaria Bioscience (LEXX) announces the engagement of the contract research organization to execute and report on its 2026 Animal Study #2 that will evaluate a number of formulation enhancements with two next-generation glucagon-like peptide-1 drugs in animals to explore the potential for improved DehydraTECH performance as well as potentially stake new intellectual property claims.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience provides update on GLP-1 oral pill market
- Lexaria Launches New GLP-1 Study to Expand Drug Delivery IP
- Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study
- Lexaria Eyes Growing Oral GLP-1 Market After Eli Lilly’s Foundayo Approval
- Lexaria Bioscience ‘applauds’ Eli Lilly’s Foundayo drug approval